Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Oct;8(5):273-6.
doi: 10.1007/s10194-007-0411-x. Epub 2007 Oct 23.

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment

Peer Tfelt-Hansen  1
Affiliations
Review

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment

Peer Tfelt-Hansen. J Headache Pain. 2007 Oct.

Abstract

The clinical efficacy in migraine was compared for oral and subcutaneous sumatriptan and naratriptan. Doses of the two administration forms were chosen as resulting in comparable blood concentrations. Subcutaneous administrations of the drugs were superior for efficacy than the oral forms. This most likely due to a quicker rise in blood concentrations after subcutaneous injections.. In designing new therapies for migraine one should aim at a quick absorption of the drug, which will probably result in an increased efficacy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Thomsen L.L., Dixon R., Lassen L.H., et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia. 1996;16:270–275. doi: 10.1046/j.1468-2982.1996.1604270.x. - DOI - PubMed
    1. Sternieri E., Pinetti D., Coccia C.P., et al. Pharmacokinetics of sumatriptan in non-responders and in adverse drug reaction reporting migraine patients. J Headache Pain. 2005;6:319–321. doi: 10.1007/s10194-005-0220-z. - DOI - PMC - PubMed
    1. Visser W.H., Burggraaf, adverse J., Muller L.M., et al. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther. 1996;60:452–460. doi: 10.1016/S0009-9236(96)90202-7. - DOI - PubMed
    1. Saxena P.R., Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J., Goadsby P.J., Ramadan N.M., Tfelt-Hansen P., Welch K.M.A., editors. The Headaches. 3. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 469–503.
    1. Tfelt-Hansen P., Vries P., Saxena P.R. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259–1287. doi: 10.2165/00003495-200060060-00003. - DOI - PubMed

MeSH terms